Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Google Secures Pentagon AI Deal for Classified Projects 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
BURLINGTON, Mass., May 01, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial, will present at the Deutsche Bank 42nd Annual Health Care Conference on Wednesday, May 3, 2017 at 2:10 p.m. EDT at the InterContinental Hotel in Boston.
To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, Zilretta™ (FX006), is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.
Corporate Contact: Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 [email protected]
